Lack of liver X receptors leads to cell proliferation in a model of mouse dorsal prostate epithelial cell

PLoS One. 2013;8(3):e58876. doi: 10.1371/journal.pone.0058876. Epub 2013 Mar 12.

Abstract

Recent studies underline the implication of Liver X Receptors (LXRs) in several prostate diseases such as benign prostatic hyperplasia (BPH) and prostate cancer. In order to understand the molecular mechanisms involved, we derived epithelial cells from dorsal prostate (MPECs) of wild type (WT) or Lxrαβ-/- mice. In the WT MPECs, our results show that LXR activation reduces proliferation and correlates with the modification of the AKT-survival pathway. Moreover, LXRs regulate lipid homeostasis with the regulation of Abca1, Abcg1 and Idol, and, in a lesser extent, Srebp1, Fas and Acc. Conversely cells derived from Lxrαβ-/- mice show a higher basal phosphorylation and consequently activation of the survival/proliferation transduction pathways AKT and MAPK. Altogether, our data point out that the cell model we developed allows deciphering the molecular mechanisms inducing the cell cycle arrest. Besides, we show that activated LXRs regulate AKT and MAPK transduction pathways and demonstrate that LXRs could be good pharmacological targets in prostate disease such as cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Cell Proliferation
  • Epithelial Cells / metabolism*
  • Gene Order
  • Gene Targeting
  • Genotype
  • Homeostasis / genetics
  • Lipid Metabolism / genetics
  • Liver X Receptors
  • Male
  • Mice
  • Mice, Knockout
  • Mitogen-Activated Protein Kinases / metabolism
  • Orphan Nuclear Receptors / genetics*
  • Orphan Nuclear Receptors / metabolism*
  • Prostate / metabolism*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction
  • Stromal Cells / metabolism

Substances

  • Liver X Receptors
  • Orphan Nuclear Receptors
  • Proto-Oncogene Proteins c-akt
  • Mitogen-Activated Protein Kinases

Grants and funding

This study was supported by research grants from Association de Recherche sur les Tumeurs Prostatiques, Ligue contre le Cancer (Allier committee), Fondation pour la Recherche Médicale (FRM), Fondation BNP-Paribas, Association pour la Recherche contre le Cancer (ARC) and Cancéropôle Lyon Rhône-alpes Auvergne (CLARA). A. Pommier and J. Dufour were funded by MNERT and ARC grants. G. Alves was funded by Région Auvergne program. H. De Boussac was funded by Région Auvergne "Nouveau Chercheur" program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.